about
Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principlesDesigning Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2Structural basis for bivalent Smac-mimetics recognition in the IAP protein familyRecognition of Smac-mimetic compounds by the BIR domain of cIAP1Structural Insight into Inhibitor of Apoptosis Proteins Recognition by a Potent Divalent Smac-MimeticSingle-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)A combinatorial approach to [1,5]benzothiazepine derivates as potential antibacterial agents.DFG-in and DFG-out homology models of TrkB kinase receptor: induced-fit and ensemble docking.Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and BortezomibAn inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic miceProapoptotic activity of a monomeric smac mimetic on human fibroblast-like synoviocytes from patients with rheumatoid arthritis.Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function.Smac127 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like SynoviocytesSmac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.Dual action Smac mimetics-zinc chelators as pro-apoptotic antitumoral agents.Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins.SPION-Smac mimetic nano-conjugates: putative pro-apoptotic agents in oncology.Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents.Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy.Peptide aldehydes as inhibitors of HIV protease.Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein.Stereoselective synthesis of conformationally constrained cyclohexanediols: a set of molecular scaffolds for the synthesis of glycomimetics.Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: SynthesisPolymer-supported silyl cyanide and silyl azide: useful reagents for solid-phase applicationsStudies on the novel anti-staphyloccal compound nematophinRegiospecific synthesis of mono-N-substituted indolopyrrolocarbazoles
P50
Q27652497-1E081D27-A60C-48EA-A731-6C5342418233Q27652810-FF373B72-3EF8-47DC-8551-4860519D91E8Q27655218-607EE930-D1EE-41FC-8863-595744DCADDFQ27665119-E1BE62F8-2206-466A-BC6B-60CC523F7DC0Q27675179-B36451AB-477A-4DD9-9A94-00D0DD625BF9Q28289589-203E014B-8D36-4F81-B3C2-2A28291EB05DQ30986136-8EF16EE6-5492-427E-9A11-84DE85589F8AQ33734233-51586A1F-5C83-40B2-BE80-9D79FD8B3A69Q33748641-83365C42-1906-4F45-85D8-C274B69360B8Q33906039-14C67EEE-E2DF-4218-A09A-91C760C538F4Q34687145-92EABD7D-919F-4609-B727-3A730249DFF1Q35033204-F90EE644-8459-4DDE-85FC-0CA215F99C78Q36265691-075BF686-22D4-4F44-950E-2DB715C3991BQ36637550-F5CD3AC7-074F-41EC-B8E4-BF9304EA7899Q37357090-1309C500-D1B9-4B03-BE2A-FF7258DC90EBQ38748928-3ABAC88C-5758-4C5C-AE04-3CA0A5C71BDFQ39003639-1791EBB6-0087-47EF-9D94-41717914E059Q39003789-88E5156C-9354-4BC9-B612-A28CB7450B76Q39260309-920CD2F4-7B82-4364-8B0B-6DD2D18049A3Q39395317-00C8A08B-AF75-4E6F-BC6C-92DA9B091C16Q39682910-F6A6FD25-1038-4012-AFFE-90732D44AC12Q39822939-B708F900-4F65-4612-BE9F-B835C403DEF9Q42558809-900C5654-E5A3-4181-9B59-085441F7467BQ44134106-AD9CBA37-B2F9-4D41-8394-235A6A82D9C7Q45359576-E4AA587B-EF1C-4C21-BBE6-3061327B4E36Q46806247-02CD838D-FD1E-4DA2-97D0-DE396B705120Q50759557-7D14AD0F-143C-4978-BE29-07ED388A945CQ56877461-C8006E89-B58D-40A4-ACFB-3A1FF3D6BF3DQ73341640-B16CE7A6-6DBA-43C0-8675-BF244808DD96Q74151481-73013C6D-7AEC-401A-B55D-1C1B4A21F600Q81320407-534430AC-3B9A-4258-8F48-F8B8FF4990A3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pierfausto Seneci
@ast
Pierfausto Seneci
@en
Pierfausto Seneci
@es
Pierfausto Seneci
@nl
Pierfausto Seneci
@sl
type
label
Pierfausto Seneci
@ast
Pierfausto Seneci
@en
Pierfausto Seneci
@es
Pierfausto Seneci
@nl
Pierfausto Seneci
@sl
prefLabel
Pierfausto Seneci
@ast
Pierfausto Seneci
@en
Pierfausto Seneci
@es
Pierfausto Seneci
@nl
Pierfausto Seneci
@sl
P1053
A-5951-2017
P106
P1153
7003844910
P21
P31
P3829
P496
0000-0001-9709-7344